Welcome to our dedicated page for Teleflex SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teleflex Incorporated (NYSE: TFX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Teleflex’s financial performance, strategic transactions, leadership changes, and capital allocation decisions.
Teleflex uses Form 8-K to report material events such as quarterly and year-to-date financial results, including revenue by region and by global product category (vascular access, interventional, anesthesia, surgical, interventional urology, OEM, and other). The company’s 8-K filings also explain its use of non-GAAP measures like adjusted revenue, adjusted constant currency revenue growth, and adjusted diluted earnings per share, with descriptions of the adjustments for items such as restructuring, impairment, acquisition and divestiture-related costs, separation expenses, regulatory compliance costs, intangible amortization, ERP implementation costs, and tax adjustments.
Filings further document significant corporate actions. For example, Teleflex has filed 8-Ks describing Equity Purchase Agreements to sell its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg, and to sell its acute care and interventional urology segments to Intersurgical Limited and related entities. These documents outline purchase price terms, closing conditions, regulatory approval requirements, and intended uses of proceeds, including share repurchases and debt reduction.
Governance and leadership developments are also captured in SEC filings. A recent Form 8-K details the departure of the company’s President and Chief Executive Officer, the appointment of Stuart A. Randle as Interim President and Chief Executive Officer, and the designation of Dr. Stephen K. Klasko as Chair of the Board, along with related compensation and severance arrangements.
On Stock Titan, these Teleflex filings are updated as they are released on EDGAR. AI-powered tools can help summarize complex disclosures, highlight key terms in 10-K and 10-Q reports, and surface notable items in Forms 4 and proxy statements, giving investors a clearer view of Teleflex’s financial reporting, insider activity, and governance structure without reading every page manually.